Cargando…
Triamcinolone acetonide and anecortave acetate do not stimulate uveal melanoma cell growth
PURPOSE: Radiotherapy-induced radiation retinopathy can develop in over 40% of eyes treated for uveal melanoma. Triamcinolone acetonide (TA) and anecortave acetate (AA) can be used to treat radiation retinopathy. It is not known whether TA or AA has any effect on potentially still viable uveal melan...
Autores principales: | el Filali, Mariam, Homminga, Irene, Maat, Willem, van der Velden, Pieter A., Jager, Martine J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Molecular Vision
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2556975/ https://www.ncbi.nlm.nih.gov/pubmed/18836566 |
Ejemplares similares
-
Triamcinolone acetonide acetate
por: Lu, Xiao, et al.
Publicado: (2011) -
Anecortave acetate in the treatment of age-related macular degeneration
por: Augustin, Albert
Publicado: (2006) -
Combination therapy with triamcinolone acetonide and bevacizumab for the treatment of severe radiation maculopathy in patients with posterior uveal melanoma
por: Shah, Nisha V, et al.
Publicado: (2013) -
Episodic Src activation in uveal melanoma revealed by kinase activity profiling
por: Maat, W, et al.
Publicado: (2009) -
Trabeculectomy with intraoperative retrobulbar triamcinolone acetonide
por: Kahook, Malik Y, et al.
Publicado: (2009)